MOH Approves CanSino As Booster Shot Mix With Pfizer Or Astra

Solution Group Berhad’s wholly-owned subsidiary, Solution Biologics Sdn Bhd, the ASEAN manufacturing partner of CanSino Biologics Inc, has received Ministry of Health approval for CanSino’s single-dose Convidecia vaccine to be used as a heterologous booster with all COVID-19 vaccines use in Malaysia.

The approval covers booster for all adults, aged 18 years and older regardless of the type of vaccine they received during their COVID-19 vaccination earlier. It is also the first and only vaccine from China to be included in the heterologous vaccination program in Malaysia that can be administered as a mix-and-match with both the Pfizer-BioNTech and the AstraZeneca COVID-19 vaccine.

The CanSino booster will be given at least three months after receiving the second dose of the primary vaccine.

Dato’ Dr. Mohd Nazlee Bin Kamal, Deputy Group Managing Director of SGB, said “We have always supported the Malaysian Government’s push for high booster coverage in the fight against the Omicron and any future variant of the virus. Thus, we can continue this push with the approval as it allows us to widen our reach to the public, especially among vulnerable groups such as the elderly and the immunocompromised”.

Recent studies in China showed that using Convidecia as a heterologous booster, via either intramuscular injection or using the inhaled version, generated greater neutralizing antibody responses than those induced by a homologous inactivated vaccine booster or heterologous recombinant protein vaccine booster.

In addition, the vaccine’s safety profile in real-life usage was also backed by the Mexican health authorities’ Events Supposedly Attributable to Vaccination or Immunization (ESAVI) Report released recently. 

“Moving forward, we are working together with CanSinoBIO to produce an inhaled version of the vaccine, which will appeal more to the children as there are no injections required. This inhaled version, which induces cellular, humoral, and mucosal immunity, is currently undergoing trials as a booster and is expected to broaden the immune response against COVID-19”.

Previous articleBerjaya Land And QSB Study Feasibility In Relocating Sabah Airport
Next articleChina’s Factory and Service Activities Improved in June, Shake Off 3 Months of Lockdown Contraction

LEAVE A REPLY

Please enter your comment!
Please enter your name here